Clinical and prognostic implications of (1,3)-beta-D-glucan in adult patients with intra-abdominal candidiasis
Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026-06 · 44 (6) · 503073
DOI: 10.1016/j.eimce.2026.503073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026-06. Verfasst von Marta Albanell-Fernández und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Service, Division of Medicines, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain; Department of Physiological Scienc…. Hauptthemen laut MEDLINE: beta-Glucans, Intraabdominal Infections, Candidiasis. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: The clinical relevance and prognostic value of serum (1,3)-beta-D-glucan (BDG) in patients with intra-abdominal candidiasis (IAC) remains poorly characterized. METHODS: We conducted a retrospective single-center study (2020-2025) in adult patients with IAC who had a BDG measurement (Fujifilm Wako β-glucan test) within ±3 days of a positive culture. Demographic, clinical, and microbiological data were collected. Outcomes included end-of-treatment and 30-day mortality, and recurrence. Statistical analyses were performed using STATA, and BDG results stratified patients. RESULTS: Among 18 IAC patients, BDG showed a sensitivity of 66.6% (95%CI: 41-86.7%). Negative BDG results were associated with a higher prevalence of Nakaseomyces glabratus (57.1% vs. 33.3%), lower end-of-treatment mortality (0% vs. 50%, P=0.05), and shorter ICU stays (median 14.5 vs. 29.5 days, P=0.01) compared with BDG-positive patients. CONCLUSION: The BDG shows limited sensitivity in IAC. Negative BDG may indicate lower fungal burden and better outcomes. Despite its limitations, BDG may represent a valuable prognostic marker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Service, Division of Medicines, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain; Department of Physiological Science, School of Medicine, Universitat de Barcelona, L'Hospitalet de Llobr…
- Department of Clinical Microbiology, Hospital Clinic-CDB, Universitat de Barcelona, Barcelona, Spain; Institute of Global Health (ISGlobal), Barcelona, Spain; CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto Salud…
- Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain; Institut d'investigació Biomèdica August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Faculty of Medicine, Univers…
- Pharmacy Service, Division of Medicines, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
- CIBER Enfermedades Infecciosas (CIBERINFEC), Instituto Salud Carlos III, Madrid, Spain; Department of Infectious Diseases, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain; Institut d'investigaci…
Zitieren
APA
Albanell-Fernández, M., Vergara, A., Herrera, S., Tuset, M., Soriano, Á., & Bodro, M. (2026). Clinical and prognostic implications of (1,3)-beta-D-glucan in adult patients with intra-abdominal candidiasis. Enfermedades infecciosas y microbiologia clinica (English ed.), 44(6), 503073. https://doi.org/10.1016/j.eimce.2026.503073
Vancouver
Albanell-Fernández M, Vergara A, Herrera S, Tuset M, Soriano Á, Bodro M. Clinical and prognostic implications of (1,3)-beta-D-glucan in adult patients with intra-abdominal candidiasis. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026;44(6):503073. doi:10.1016/j.eimce.2026.503073
BibTeX
@article{AlbanellFernndez2026,
author = {Albanell-Fernández, Marta and Vergara, Andrea and Herrera, Sabina and Tuset, Montse and Soriano, Álex and Bodro, Marta},
title = {Clinical and prognostic implications of (1,3)-beta-D-glucan in adult patients with intra-abdominal candidiasis},
journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
year = {2026},
volume = {44},
number = {6},
pages = {503073},
doi = {10.1016/j.eimce.2026.503073}
}
EUVIMED